Gut-microbiome metabolite supplement

Urolithin A

Urolithin A is a gut-microbiome metabolite of ellagitannin-rich foods; a 2022 trial report cites a half-life of about 24 hours, and the app lists 19 hours.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Urolithin A after one dose: 50% at ~19 h, 25% at 38 h, 12.5% at 57 h.

Drawn from the half-life in the app's model, ~19 h. The model's figures

Andreux and colleagues (Amazentis SA and the École Polytechnique Fédérale de Lausanne, Nature Metabolism, 2019) describe urolithin A as a "natural dietary, microflora-derived metabolite".2 Gut bacteria make it from dietary ellagic acid and ellagitannins such as punicalagin, which occur in pomegranate, certain berries, walnuts and pecans.1 The app's notes say only about 30% of people produce it endogenously; the same paper cites earlier, smaller studies that put the natural ability to produce urolithins at 30 to 60%.1 In a trial of 100 adults funded by Amazentis SA, "Only 12% of subjects had detectable levels of UA at baseline", and after a glass of pomegranate juice "~40% of the subjects converted significantly the precursor compounds into UA" (Singh and colleagues, European Journal of Clinical Nutrition, 2022).1 The supplement form in the app's notes, Mitopure, is named in some of the trial reports below; one report calls it "UA (Mitopure, Amazentis SA)".3

The app grades the evidence as moderate. Amazentis SA funded or supported the exposure study and the middle-aged, older-adult, immune and distance-runner trials described below.1,4,5,3,6 The authors of the exposure paper declare that five of them are employees, two are board members and two are members of the scientific advisory board of Amazentis SA.1 The resistance-training trial reports funding from the 14th five-year Education Plan of Jiangsu Province, and the obesity trial from the American Heart Association and the Reynolds Foundation.7,8 The record of the heart-failure crossover trial available here carries no funding statement.9

Urolithin A is described as a mitophagy activator; the 2022 exposure paper defines mitophagy as "the recycling of defective cellular mitochondria".1 Urolithins are "absorbed and conjugated in the liver and are subsequently excreted in urine and feces".1 In human muscle, the middle-aged adult trial reports that its data "revealed UA to impact markers of Parkin-mediated mitophagy and to dose-dependently upregulate levels of mitochondrial TCA cycle and OXPHOS proteins".4 In the immune trial, the authors state that they "did not formally investigate the activation of classical mitophagy or autophagy programs in this trial", and that their in vitro experiments "use much higher concentrations than the physiological levels achieved in the clinical setting".3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~19 h
Bioavailability
80%
Typical dose
500–1,000 mg/day
Route
Oral
Time to peak
~6 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 19 hoursAbout 24 hours ("a half-life of ~24 h") and "approximately a day", both stated in the discussion of a 2022 trial in 100 adults that sampled plasma only at baseline, 6 h and 24 h; the figures are attributed there to earlier work, not measured in that trial1
Bioavailability80%No oral bioavailability percentage is reported in the full-text trial reports cited here (the 2019 first-in-human and heart-failure trials were available only as short records), which give plasma concentrations of urolithin A and its conjugates; the FDA letter relays Amazentis's summary of a rat study that "demonstrates low absorption (<2.2%)", an animal result1,10
Time to peakAbout 6 hoursA 2022 trial gave 500 mg in a food product and sampled plasma only at baseline, 6 h and 24 h; mean urolithin A glucuronide was 480.75 ± 238.03 ng/mL at 6 h and 255.52 ± 129.38 ng/mL at 24 h, and the paper cites earlier first-in-human work for peak concentrations "at 6 h after intake"1

In that trial, plasma urolithin A glucuronide exposure was "six-fold higher in the Mitopure group than the PJ group".1 No full-text paper cited here measured a half-life directly; the 2019 first-in-human trial was available only as a short record, and the only half-life figures found are the two quoted from the 2022 exposure paper, which attributes them to earlier work.1

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once daily, as in the older-adult trial5.

An illustration from a pharmacokinetic model using a half-life of 19 hours. It is not a measured level or a suggested dose.

4

Human studies

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Andreux and colleagues, Nature Metabolism 20192First-in-human trial; authors at Amazentis SA2Healthy, sedentary elderly individuals2A single dose, or multiple doses over a 4-week period; effects reported at 500 mg and 1,000 mg2"UA has a favourable safety profile (primary outcome)", "UA was bioavailable in plasma at all doses tested"; plasma acylcarnitines and muscle mitochondrial gene expression modulated (secondary outcomes)2
Liu and colleagues, JAMA Network Open 20225Double-blind, placebo-controlled; supported by Amazentis SA566 adults aged 65 to 90 years (33 per group)51000 mg a day or placebo for 4 months5Primary endpoints (6-minute walk distance, hand-muscle ATP production) not significantly different from placebo; muscle endurance, a secondary end point, was better at 2 months but not significantly different at 4 months, and plasma acylcarnitines, ceramides and C-reactive protein were lower with urolithin A at 4 months5
Singh and colleagues, Cell Reports Medicine 2022 (ATLAS)4Single-centre, randomised, double-blind, placebo-controlled; funded by Amazentis SA488 untrained, overweight, middle-aged adults4Placebo (n = 29), 500 mg (n = 29) or 1,000 mg (n = 30) a day for 4 months4Primary endpoint, peak power output, not significantly different from placebo; hamstring peak torque +12% (500 mg) and +9.8% (1,000 mg) against placebo4
Denk and colleagues, Nature Aging 2025 (MitoImmune)3Randomised, double-blind, placebo-controlled; Amazentis SA funded it and supplied the product350 healthy adults aged 45 to 70 years31,000 mg a day (n = 25) or placebo (n = 25) for 28 days3Primary: naive-like CD8+ cells +0.50 percentage points (95% CI 0.16 to 0.83; P = 0.0437); CD8+ fatty acid oxidation capacity +14.72 percentage points; separately, pro-inflammatory cytokine trends, assessed in at most 20 participants, did not reach significance3
Whitfield and colleagues, Sports Medicine 20256Double-blind, parallel-group, placebo-controlled; supported by Amazentis SA642 competitive male distance runners61000 mg a day (n = 22) or placebo (n = 20) for 4 weeks at an altitude training camp63000 m time trial not significantly improved in either group; perceived exertion lower with urolithin A (p = 0.02); no significant time by treatment interaction for aerobic capacity (p = 0.138)6
Pinaffi-Langley and colleagues, JAMA Network Open 20268Single-site, double-blind, placebo-controlled; funded by the American Heart Association and the Reynolds Foundation; no conflicts reported850 adults aged 40 to 64 years with a body mass index of 30 or greater (25 active, 25 control)81000 mg or placebo for 4 weeks8Primary outcome, brachial artery flow-mediated dilation, did not differ significantly (control 0.3% [5.1%]; active 1.3% [7.6%]); seven participants (14%) lost to follow-up8
Dao and colleagues, Frontiers in Nutrition 2026 (systematic review)11Systematic review of randomised trials published up to December 2025; no conflict reported by the authors of the review11Five randomised trials, n = 23611Oral urolithin A against placebo11Only the 6-minute walk test could be pooled (two trials): +17.03 m (95% CI -5.33 to 39.40 m; p = 0.135), certainty rated low11

Deeper analysis: older adults, 4 months (Liu and colleagues, 2022)

Liu and colleagues (University of Washington, with authors at Amazentis SA) reported the trial in JAMA Network Open in 2022: 66 adults aged 65 to 90 years, mean age 71.7 years, 75.8% women, all White, in Seattle.5 The primary end points were "change from baseline in the 6-minute walk distance and change from baseline to 4 months in maximal ATP production in the hand skeletal muscle".5 The mean change in walk distance was 60.8 m with urolithin A against 42.5 m with placebo.5 The authors write that "This increase with urolithin A was not a significant improvement over that observed in the placebo group".5 Maximal ATP production did not differ either: "There was no significant effect of treatment on the mean (SD) change in maximal ATP production from baseline to 4 months in either the hand FDI".5 At the 2-month visit, muscle endurance, a secondary end point, was significantly better in two muscles, but at 4 months "a parallel increase in the placebo group led to no significant effect of treatment".5 The authors report 33 adverse events, none serious, with no statistical differences between groups; the table lists 18 events with urolithin A against 15 with placebo, one withdrawal in each group, and increased liver enzymes in 2 participants on urolithin A and none on placebo.5 Their stated limitations include that the 6-minute walk distance "significantly improved from baseline in both the placebo and the urolithin A groups", that "monitoring daily participant physical activity was not part of the trial protocol", and the "relatively small sample size of only White participants from the Seattle, Washington, area".5 The paper states: "This research was supported by Amazentis SA", and that the funder "had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication".5 Among the disclosures, one author reported "being the founder, the chief executive officer, and a board member of Amazentis SA" and another "being the chair of the board and a shareholder of Amazentis SA".5

Deeper analysis: middle-aged adults, 4 months (Singh and colleagues, 2022)

Singh and colleagues (Amazentis SA and the École Polytechnique Fédérale de Lausanne) reported the ATLAS trial in Cell Reports Medicine in 2022, with 88 untrained, overweight, middle-aged adults randomised to placebo (n = 29), 500 mg (n = 29) or 1,000 mg (n = 30) a day for 4 months.4 "Nine subjects did not complete the study (n = 9 dropouts)".4 For the pre-specified primary endpoint, peak power output, "No significant change in PPO" was seen against placebo, with non-significant increases of about 4% in both urolithin A groups.4 Hamstring peak torque rose 12% (p = 0.027 against placebo) at 500 mg and 9.8% (p = 0.029) at 1,000 mg, while quadriceps changes were "positive, although non-significant".4 C-reactive protein was lower at both doses, "statistically significant at the 1,000 mg dose", while plasma acylcarnitines fell at 500 mg and "No changes occurred in the UA 1,000 mg cohort".4 Adverse events: "A total of 102 post-emergent adverse events (AEs) were reported by a total of 45 participants", 42 events in 17 placebo participants, 24 in 13 on 500 mg and 36 in 15 on 1,000 mg.4 The authors list as a main limitation that "the primary endpoint of the study, PPO, was not significantly different between the UA groups versus the placebo group", and call the study a "proof-of-concept study".4 "This study was funded by Amazentis SA", and the disclosure states that six authors are employees, two are board members and two sit on the scientific advisory board of Amazentis SA, "who is the sponsor of this clinical study".4

Deeper analysis: immune markers, 4 weeks (Denk and colleagues, 2025)

Denk and colleagues (Georg-Speyer-Haus and Goethe University Frankfurt, with authors at Amazentis SA) reported the MitoImmune trial in Nature Aging in 2025.3 It was a "single-center, randomized, double-blind, placebo-controlled, investigator-initiated interventional trial" in 50 healthy adults aged 45 to 70, given 1,000 mg a day (n = 25) or placebo (n = 25) for 28 days.3 The registry entry lists Amazentis SA as lead sponsor and the status as completed.12 On the primary outcomes, naive-like CD8+ cells expanded by 0.50 percentage points (95% CI 0.16 to 0.83; P = 0.0437) and CD8+ fatty acid oxidation capacity by 14.72 percentage points (95% CI 6.46 to 22.99; P = 0.0061).3 The authors write that the cytokine analysis, limited to a maximum of 20 participants, "remains underpowered", and that trends for pro-inflammatory cytokines "failed to achieve statistical significance".3 They also state that the single-cell sequencing comparisons "do not respect randomization and are to be considered of explorative nature", that a pre-specified secondary end point (epigenetic age of blood cells) is not reported because the data "were analysed after unblinding", and that no long-term follow-up was done.3 Safety: "only a total of nine adverse events were recorded", four with urolithin A and five with placebo, mostly upper respiratory tract infections; one placebo participant stopped intake after a major depressive episode "deemed unrelated to the intervention".3 The paper states that Amazentis SA "funded this clinical study and provided the investigational product (Mitopure)", that three authors are Amazentis employees, that its president is an author, and that one author "has received consulting fees from Amazentis".3 A 2026 Author Correction to this article is listed in PubMed; its content was not assessed here.3

Deeper analysis: distance runners, 4 weeks (Whitfield and colleagues, 2025)

Whitfield and colleagues (Australian Catholic University, with three authors at Amazentis SA) reported the trial in Sports Medicine in 2025: 42 competitive male distance runners given 1000 mg a day (n = 22) or placebo (n = 20) for 4 weeks during an altitude training camp.6 In the 11 runners per group who ran the 3000 m time trial, "Running performance (3000 m time trial) was not significantly improved in either treatment group (UA; p = 0.116, PL; p = 0.771)".6 Urolithin A "significantly lowered ratings of perceived exertion (RPE, p = 0.02)" and "reduced indirect markers of post-exercise muscle damage" after the time trial, although creatine kinase levels "were not impacted by UA supplementation in response to a ~4.5 km downhill run".6 The authors add that "CK levels in the UA group were higher than the PL group in Race 1 and during the downhill runs".6 There was no significant time by treatment interaction for aerobic capacity (p = 0.138), and the placebo group also rose (3.6 ± 1.3%).6 In muscle biopsies, "While not statistically significant, UA led to a medium effect for increased markers of mitophagy", without changes in mitochondrial function.6 The authors conclude that urolithin A "did not further enhance performance in highly trained male endurance athletes".6 The full text fetched for this trial contains no adverse-event results; it reports that 44 runners were recruited, one was lost to follow-up and one "withdrew with severe illness partway through the investigation, unrelated to the treatment", leaving 42 in the analysis.6 The paper reports support from Amazentis SA, which it calls "the sponsor of this clinical study", with three authors employed there and one author receiving travel support from it.6 The registry entry's summary text describes 36 runners, while its enrollment field lists 42 (actual), the same as the 42 in the paper.13,6

Deeper analysis: obesity and vascular function, 4 weeks (Pinaffi-Langley and colleagues, 2026)

Pinaffi-Langley and colleagues (University of Oklahoma) reported in JAMA Network Open in 2026 a single-site trial of 50 adults with obesity; the primary outcome, brachial artery flow-mediated dilation, "did not differ significantly based on group allocation".8 There was "no significant treatment effect on secondary peripheral endothelial function outcomes", while task-evoked cerebrovascular responses were significantly greater with urolithin A and "task performance remained unchanged".8 Of 50 enrolled, 43 completed, and 22 participants reported 43 adverse events, with headache the most common.8 The authors list "a small sample size, short duration, and was conducted at a single site" among their limitations, and the sponsor "had no role in the design and conduct of the study".8

Other trials

Zhao and colleagues gave 1 g a day for 8 weeks to twenty resistance-trained male athletes; against placebo, 1RM bench press and squat rose without reaching significance (p = 0.462; p = 0.710), while isometric contraction (p = 0.048) and repetitions to failure (p = 0.011) improved significantly.7 Jamialahmadi and colleagues gave 500 mg twice daily or placebo in two 4-week periods to 10 patients with heart failure with reduced ejection fraction, and report no significant effect on echocardiographic measures, pro-BNP, glucose or CRP, but higher HDL cholesterol with urolithin A (+6.46 ± 2.33 mg/dL, p = 0.026).9 The resistance-training trial reports no conflict of interest, and its stated limitations are that "The inclusion of participants from a single gender and the limited range of exercise types represent the primary limitations of this research", with diet as a potential confounder.7 The heart-failure crossover trial concluded that its results "do not support any positive effect of UA supplementation in improving echocardiographic and biochemical indices of HFrEF".9 For the 2019 first-in-human trial, only the PubMed record with its summary was available, so group sizes, adverse events and limitations are not reported here.2

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels9 rows
SourceDose and routeLengthComparator and people
Andreux and colleagues 20192Oral; effects reported at 500 mg and 1,000 mgSingle dose, or 4 weeksHealthy, sedentary elderly individuals; comparator and number not in the record fetched
Singh and colleagues 2022, exposure study1500 mg urolithin A in a food product (stirred into yogurt)Single intake per period, crossoverPomegranate juice (8 fl. oz); 100 adults
Liu and colleagues 202251000 mg a day, oral4 monthsPlacebo; 66 adults aged 65 to 90 years
Singh and colleagues 2022, ATLAS4500 mg or 1,000 mg a day, oral4 monthsPlacebo (n = 29); 88 adults in total
Denk and colleagues 202531,000 mg a day, oral28 daysPlacebo (n = 25); 50 adults
Whitfield and colleagues 202561000 mg a day, oral4 weeksPlacebo (n = 20); 42 runners
Zhao and colleagues 202471 g a day, oral8 weeksPlacebo; 20 athletes
Jamialahmadi and colleagues 20249500 mg twice daily, oralTwo 4-week periods with a 2-week washoutPlacebo in crossover; 10 patients
Pinaffi-Langley and colleagues 202681000 mg, oral (softgel capsules per the registry entry)8,144 weeksPlacebo; 50 adults

The app lists 500 to 1,000 mg a day, matching the daily doses in the trials above.

In the exposure study, 26 adverse events followed pomegranate juice and 15 followed the 500 mg product; no serious adverse events were reported, all participants completed the study, and the paper describes the events as "most of which were mild and resolved during the study".1 In older adults, the authors report "No statistical differences in adverse events were observed between the 2 groups".5 In the obesity trial, headache was the most reported event, and the authors describe supplementation as "well tolerated and feasible".8 In the resistance-training trial, C-reactive protein was significantly higher than at baseline in the urolithin A group (Δ = 0.71 ± 0.21 mg/L, p = 0.001), and significantly lower than in the placebo group (Δ = -0.79 ± 0.38 mg/L, p = 0.032).7 The same trial states that "All participants exhibited good tolerability throughout the intervention period and one month following the completion of the testing, with no adverse events reported".7 For animals, the FDA letter relays the notifier's statements that 28-day and 90-day rat studies observed "no toxicologically significant effects" and "no adverse toxicological effects" at the highest levels tested.10

7

Bloodwork and markers

Sources in this part

  1. 3Denk et al., 2025

The app lists no markers to monitor for urolithin A. In the immune trial, "No significant changes were observed in kidney function parameters or liver enzymes after the 28 days of either UA or placebo".3

8

Regulatory and anti-doping status

The FDA's letter for GRAS Notice GRN 000791 states that it received the notice, submitted on behalf of Amazentis SA, on 15 June 2018 and filed it on 9 July 2018.10 The notice covers urolithin A as a food ingredient at up to 500 mg per serving in some products and up to 1000 mg per serving in Greek yogurts, high protein yogurts and milk-based protein shakes.10 The FDA states that it has "no questions at this time regarding" the notifier's conclusion that the use is GRAS.10 The letter adds that it "is not an affirmation that urolithin A is GRAS under 21 CFR 170.35".10 It relays Amazentis's description of the manufacturing method, in which "Urolithin A is chemically synthesized using one of two alternative processes".10 No DailyMed drug label for urolithin A was identified. Urolithin A is not named in the text of the WADA Prohibited List 2026, whose effective date is 1 January 2026.15 Several classes on the list also cover "other substances with a similar chemical structure or similar biological effect(s)", so absence by name is not a statement on every class.15

No full-text paper cited here measured urolithin A's half-life or oral bioavailability percentage directly (the 2019 first-in-human trial was available only as a short record), so the app's 19 hours and 80% have no measured figure beside them in these sources.1 The longest randomised trial reviewed here lasted 4 months, and the authors of the older-adult trial call for "a longer intervention of more than 6 months" in future studies.5 Whether the changes in biomarkers translate into clinical benefit is not established in the sources: the immune-trial authors state that further studies are needed on "clinically tangible benefits", and the systematic review calls the narrative findings "exploratory and hypothesis-generating".3,11 The systematic review states that "Larger, longer, and methodologically standardized trials in better-defined populations are required".11 The resistance-training and obesity trials report other funders and enrolled 20 and 50 participants; the heart-failure trial, with 10 patients, has no funding statement in the record available here.7,8,9 ClinicalTrials.gov lists further urolithin A trials, for example in prostate cancer and COPD, whose results were not assessed here.

What is urolithin A?

Urolithin A is a "natural dietary, microflora-derived metabolite" that gut bacteria produce from ellagitannin-rich foods.2,1

What is the half-life of urolithin A?

The 2022 exposure paper cites a half-life of about 24 hours ("~24 h"), and the app lists about 19 hours.1 The paper attributes the figure to earlier work and sampled plasma only at baseline, 6 h and 24 h.1

How long does urolithin A take to reach its peak level in blood?

The 2022 exposure paper cites peak concentrations "at 6 h after intake", and the app lists about 6 hours.1 In that trial, mean urolithin A glucuronide was 480.75 ± 238.03 ng/mL at 6 h and 255.52 ± 129.38 ng/mL at 24 h after a 500 mg product.1

Does everyone make urolithin A from food?

No: in a trial of 100 adults, 12% had detectable urolithin A glucuronide at baseline and about 40% became high converters 24 hours after pomegranate juice.1

Is urolithin A banned by WADA?

Urolithin A is not named in the text of the WADA Prohibited List 2026.15 Some classes on the list also cover "other substances with a similar chemical structure or similar biological effect(s)".15

Has the FDA approved urolithin A?

No FDA approval of urolithin A as a drug was identified; the FDA letter on GRAS Notice GRN 000791 says it has "no questions at this time" about the notifier's conclusion and "is not an affirmation that urolithin A is GRAS".10

Did the human trials meet their primary endpoints?

Three trials did not meet their primary endpoints: the older-adult trial (walk distance and muscle ATP production), the middle-aged trial (peak power output) and the obesity trial (flow-mediated dilation).5,4,8 The distance-runner trial named two primary endpoints, creatine kinase and 3000 m time trial performance, and the time trial was not significantly improved in either group.6 The immune trial reported significant differences on its primary outcomes (P = 0.0437 and P = 0.0061).3

What did the systematic review of urolithin A trials conclude?

The 2026 systematic review of Dao and colleagues included five randomised trials (n = 236) and called the evidence "five small, short-term trials in clinically heterogeneous populations".11 Its only pooled outcome, the 6-minute walk test, gave +17.03 m (95% CI -5.33 to 39.40 m), described as "statistically inconclusive" with low certainty.11

12

References

  1. Singh A, et al. Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. Eur J Clin Nutr 2022. PMID 34117375
  2. Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab 2019. PMID 32694802
  3. Denk D, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nat Aging 2025. PMID 41174221
  4. Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med 2022. PMID 35584623
  5. Liu S, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Netw Open 2022. PMID 35050355
  6. Whitfield J, et al. Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners. Sports Med 2025. PMID 40839339
  7. Zhao H, et al. Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study. J Int Soc Sports Nutr 2024. PMID 39487653
  8. da Costa Pinaffi-Langley AC, et al. Urolithin A and Endothelial and Cerebrovascular Function in Middle-Aged Adults With Obesity: A Randomized Clinical Trial. JAMA Netw Open 2026. PMID 42853569
  9. Jamialahmadi T, et al. Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial. Rev Recent Clin Trials 2024. PMID 38415449
  10. U.S. Food and Drug Administration. Response letter to GRAS Notice No. GRN 000791 (urolithin A), submitted on behalf of Amazentis SA. FDA GRAS letter
  11. Dao T, et al. Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. Front Nutr 2026. PMID 42559151
  12. ClinicalTrials.gov. NCT05735886. Urolithin A Supplementation to Boost Immune Health. NCT05735886
  13. ClinicalTrials.gov. NCT04783207. Effects of Mitopure (Urolithin A) on Skeletal Muscle Function, Iron Metabolism and Endurance Performance. NCT04783207
  14. ClinicalTrials.gov. NCT05921266. Urolithin A Supplementation in Middle-aged Adults With Obesity. NCT05921266
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list